Skip to content

The added value of home spirometry in paediatric blended asthma care

Assessing the added value of home spirometry in secondary prevention and healthcare cost reduction within blended paediatric asthma care (SPIRO-PREVENT) - The value of home spirometry in paediatric blended asthma care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON61217
Enrollment
166
Registered
2025-10-17
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma Asthma

Interventions

Blended care with the addition of home spirometry.&nbsp

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
2 Years to 15 Years

Inclusion criteria

Inclusion criteria: Informed consent of parents, and of children 12 years and older;  Doctor’s diagnosed asthma, preferably supported with documented significant bronchodilator response to adequate dosage of salbutamol and/or a positive bronchial provocation test;at least 6 months treated by paediatrician or paediatric pulmonologist;  6-16 yrs of age;   Severe/difficult to treat asthma, defined as two or more items of:  Treatment step 3 (according to the Dutch Guideline) or higher, or use of biologicals;  At least 1 hospital ICU admission in the last 24 months; At least 1 hospital admission or 2 courses of prednisone in the last 12 months;   At least 2 unscheduled visits to the ER and/or General Physician in the last 12 months. Chronic poor asthma control, defined as 2 or more exacerbations requiring Oral corticosteroids, 3 times an ACT< 20, or prescription of 6 or more cannisters of short acting B2- agonists per year;(willing to) Use Luchtbrug as part of routine asthma care. 

Exclusion criteria

Exclusion criteria: Other chronic conditions interfering with this study/asthma:Prematurity < 36 weeks;Cardiopulmonary, neuromuscular or metabolic condition;Other pulmonary diseases.No access to internet or smartphone;   Unable to understand spoken or written Dutch;   Inability to conduct (home) spirometry reliably/reproducibly. 

Design outcomes

Primary

MeasureTime frame
This study has co-primary objectives that are evaluated hierarchically. The primary clinical objective is to demonstrate non-inferiority of asthma control, measured by the Asthma Control Test (ACT) or childhood-ACT (c-ACT), in children receiving blended care with the addition of home spirometry compared with children receiving blended care alone. Conditional on demonstrating non-inferiority of asthma control, the second objective is to assess the difference in direct healthcare costs between these two care strategies.

Secondary

MeasureTime frame
Secondary endpoints are indirect healthcare costs, number of hospital visits and/or admissions, courses of prednisone, unscheduled medical consultations, adherence to treatment, self-management skills, quality of life and patient satisfaction.  

Countries

Netherlands

Contacts

Public ContactM.C.L. Kleuskens

Radboud Universitair Medisch Centrum

mirese.kleuskens@radboudumc.nl0622308709

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026